Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 3/20 | 0.47 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.45 |
| ▸ | CHUK | O15111 | 4/20 | 0.44 |
| ▸ | INSR | P06213 | 4/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 4/20 | 0.44 |
| ▸ | CAMKK2 | Q96RR4 | 4/20 | 0.44 |
| ▸ | CLK2 | P49760 | 3/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | CLK3 | P49761 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1838178 | 0.91 | CDC7 (0.51) | CDC7DYRK1ACHUKINSRMAPK8 | |
| SCHEMBL1841792 | 0.89 | EGFR (0.53) | CHUKINSRMAPK8CAMKK2EGFR | |
| SCHEMBL1841326 | 0.87 | AURKA (0.48) | DYRK1ATBK1CHUKINSRMAPK8 | |
| SCHEMBL1840172 | 0.85 | CHUK (0.56) | CDC7TBK1CHUKINSRMAPK8 | |
| SCHEMBL1840513 | 0.85 | GSK3B (0.46) | CDC7DYRK1ATBK1CLK2MAPT | |
| SCHEMBL1842220 | 0.84 | CCNK (0.58) | DYRK1ATBK1CLK2EGFRMAPT | |
| SCHEMBL1840648 | 0.84 | CHUK (0.60) | CDC7CHUKINSRMAPK8CAMKK2 | |
| SCHEMBL1840354 | 0.83 | CDC7 (0.52) | CDC7DYRK1APIK3C3MAPT | |
| SCHEMBL1836679 | 0.81 | PIK3CD (0.46) | CDC7DYRK1ACHUKINSRMAPK8 | |
| SCHEMBL31240700 | 0.77 | CLK2 (0.58) | DYRK1ATBK1CLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011526931-A | — | — | 2011-10-20 | — | — | JP | claimed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | claimed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | claimed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | CDC7 79/4885DYRK1A 546/4885TBK1 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.